Join today and have your say! It’s FREE!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}

Join today with :

or

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Sign in with existing account
Please Try Again
{{ error }}

Sign In With :

or

Password Hint : {{passwordHint}}
Forgot Password?
Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Immuron Limited IMRN

Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's lead product candidate, IMM-124E, is a proprietary immunomodulator agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyp

View modes: 

it's a buy today for me

got in this morning,so glta shareholders.  rate and reply

RE:2018 Liver Meeting Presentation by Sanyal

Upon re-read, the data looks quite promising. Earlier results had few details so it was nice to see the data. I expect a large pharma to want a piece of the action here. Let's see who will step up...read more

Former Health Canada Senior Regulatory Compliance Officer joins Nextleaf

"The serious regulatory infractions by several large Canadian licensed cannabis producers, along with an expanded scope of cannabis products through legalization 2.0, reinforces the critical role that compliance oversight plays in building a cannabis company all stakeholders can be proud of," stated Paul Pedersen, co-founder and CEO of Nextleaf Solutions. "Sherry is ...read more

2018 Liver Meeting Presentation by Sanyal

The presentation is now out. Who can figure out what the results mean to the corporate valuation since it was quite a technical oriented presentation. Do the other players see these markers as...read more

×

StockTalk
Get our FREE StockTalk Investor Guides by sector as they are released!

Stay on top of sector specific news, get industry leaders insights and our best content, delivered to your email.

You are already a member! Please enter your password to sign in.